Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement

Ali Hammad, Yoshiaki Tsukada, Nelson Torre

Abstract
A 35 year old woman with systemic lupus erythematosus and hypocomplementaemia presented with new onset seizures and subsequently died. At necropsy, widespread microinfarctions of the cerebral cortex were found to be predominantly due to the formation of leucoaggregates within small blood vessels without any vasculitis.

Despite recent advances in the understanding of the pathophysiology of systemic lupus erythematosus (SLE), the pathogenesis of some complications of SLE remains enigmatic and, in some instances, more than one mechanism may be responsible for a similar complication. Considerable controversy surrounds the pathogenesis of central nervous system disease in SLE. We report here an unusual case in an attempt to explain a mechanism that may play a part in central nervous system disease in SLE.

Case report
A 35 year old woman with a history of SLE was admitted to the Sisters of Charity Hospital with rapidly progressive shortness of breath. She had been in good health until three years before this admission when she was admitted to hospital for polyarthritis. Pertinent laboratory data at that time were as follows: haemoglobin 101 g/l, packed cell volume 30.3%, platelets 135×10⁹/l, microscopic haematuria, 2+ proteinuria, positive antinuclear antibody screen (titre 280, homogeneous), positive antibodies to double stranded DNA (titre 1/320), total complement 22% of reference (normal 51–150%), C3 0.29 g/l (normal 0.7–1.76 g/l), C4 0.05 g/l (normal 0.18–0.45 g/l). Serum electrolytes, blood urea nitrogen, and creatinine were normal. Rheumatoid factor and anticyclic citrullinated peptide antibodies were absent. A diagnosis of SLE was made.

The patient also developed immune thrombocytopenia and her platelet counts reached a minimum of 39×10⁹/l. High dose prednisone resulted in an amelioration of symptoms and an increase of the platelet count to normal levels. A renal biopsy, performed two months later, showed a mild and sparse sclerosing and proliferative glomerulonephritis. Proteinuria was quantified at 2.2 g/day. She continued to have low C3 and C4 levels and developed a vasculitic rash on her hands and feet. She was then treated with azathioprine and prednisone for approximately seven months with improvement. Subsequently, she developed maxillary sinusitis requiring admission to hospital and treatment with antibiotics. At that time, azathioprine was stopped and prednisone was decreased to 20 mg/day. Two months before this admission she developed a Mycobacterium chelonae infection of the skin of the left upper arm and was admitted to the hospital for intravenous treatment with antibiotics. At the time of this admission she was receiving prednisone (20 mg/day).

On examination she was alert and oriented but obviously dyspneic. Vital signs were as follows: blood pressure 150/70 mmHg, temperature 37°C, pulse 120 beats/minute, respiratory rate 32 breaths/minute. Jugular venous distention was noted. An S4 gallop was heard. Her lungs were clear and her abdomen was normal. No focal neurological deficits were noted. Serum sodium, potassium and glucose were normal. Creatinine was 117 mmol/l and lactate dehydrogenase was 1488 U/l. Liver enzymes were normal. Her white blood cell count was 12.7×10⁹/l, haemoglobin was 100 g/l, packed cell volume was 31. Urine analysis showed a specific gravity of 1.023, pH 5, protein 3+, red blood cell count 10–20/high powered field, white blood cell count 2–5/high powered field, bacteria 1+, and no leucocyte esterase or glucose. The coagulation profile was normal. Blood, urine, and sputum specimens were obtained for culture. An electrocardiogram showed sinus tachycardia with a non-specific ST abnormality. Echocardiography showed diffuse hypokinesis, a left ventricular ejection fraction of 25–30%, and a moderate sized thrombus in the left ventricle. Shortly after presentation, she developed intermittent tonic clonic seizure activity. Intravenous heparin for possible cerebral emboli and high dose parenteral corticosteroids for possible vasculitis were begun. She developed cardiac arrest from which she was promptly and successfully resuscitated, but she then remained comatose and hypotensive. Arterial blood gas determinations showed a severe and persistent metabolic acidosis. Empirical treatment with antibiotics was begun with cefoxitin, amikacin, and erythromycin. A computed tomography scan of the brain showed multiple cortical infarctions without intracranial haemorrhage. The patient then developed acute renal failure with anuria. She finally succumbed to her multisystem disease less than 48 hours after admission. Cultures of blood, urine, and sputum remained negative.

At necropsy, anasarca was noted. The heart showed concentric hypertrophy but no mural thrombus was found. The lungs showed severe...
passive congestion. No vasculitis was found in the heart or the lungs. The kidneys were shrunken and showed severe glomerulosclerosis and crescentic glomerulonephritis. The pathology of the brain was important. Multiple small cortical infarctions were seen scattered throughout the cerebral hemispheres (fig 1). Microscopic examination showed these infarctions to be one to two days old with acute ischaemic changes of the neurones and polymorphonuclear infiltration. A few older microscopic infarcts were present. The vessels in the areas of infarction were normal in appearance and free of any vasculitic process. A main pathological process appeared to be occlusion of these small vessels by aggregates of leucocytes (fig 2). Occlusion of small vascular lumens by fibrin thrombi was rare (fig 3). A few small vessels showed Virchow-Robin spaces filled with leucocytes, representing extension of leucocytes from the subarachnoid space (fig 4).

Discussion

The clinical manifestations of central nervous system disease in SLE are protean. They include seizures, cranial nerve disorders, hemiparesis, paraparesis, peripheral neuropathy, movement disorders, meningeal signs, and autonomic disorders. Psychiatric manifestations and disorders of mental functions are also well described. The pathogenesis of central nervous system disease in SLE, however, remains ill defined. In one necropsy series, the major neuropathological findings included vasculopathy, infarction, haemorrhage, and infection. Vasculopathy was found in 65% of the studied cases and was further subclassified as vascular hyalination, perivascular inflammation, endothelial proliferation, thrombosis, and, rarely, vasculitis. Antiphospholipid antibodies, which may be present in up to 44% of patients with SLE, have also been associated with an increased propensity towards thrombosis. Complement probably has an important part to play in vascular injury in SLE. The role of immune complexes in complement activation is well established. Autoantibodies against
nuclear antigens, especially double stranded DNA, result in the formation of immune complexes that deposit within the walls of small vessels and activate complement at the site of deposition. Nevertheless, some lupus patients have small vessel occlusive disease without any evidence of immune complex deposition. This could be explained on the basis of intravascular activation of complement via the alternative pathway as a cause of activation and aggregation of inflammatory cells in SLE.

In 1988 Hopkins et al 7 reported two patients who died during an acute lupus flare and, at necropsy, were found to have cerebral and intestinal infarctions. Microscopy failed to show any fibrin thrombi or vasculitis. Many vessels, however, were found to be occluded by aggregates of neutrophils. They suggested that circulating anaphylatoxins, C3a and C5a, products of intravascular complement activation, may result in occlusive vasculopathy by aggregation of leucocytes and platelets in a manner similar to the endotoxin induced Shwartzman reaction. These leucotrophs can result from the increased adhesiveness of the polymorphonuclear cells to the subendothelial surface of small vessels. Such increased adhesiveness has been induced in vitro by lipopolysaccharide, interleukin 1, and tumour necrosis factor.

Cytokines, such as interleukin 1 and tumour necrosis factor, and bacterial endotoxin lipopolysaccharide can induce the formation of polypeptide endothelial leucocyte adhesion molecules (ELAM 1) on the surface of cultured human endothelial cells. 10 Theoretically, in SLE, in addition to interleukin 1 and tumour necrosis factor, complement split products, immune complexes, and anticitrullin antibody may be responsible for such an increase in vascular adhesiveness.

In the patient reported here, we were able to show a good correlation between clinical signs (seizures and coma) and pathological findings (diffuse cortical infarcts of various ages). Microscopically, the predominant lesion was that of occlusive vasculopathy due to aggregation of leucocytes within vessels subtending infarctions (fig 2). The patient had low CH50, C3, and C4 levels throughout the course of her illness. This probably represented continually active disease and ongoing complement activation with inflammation. Complement activation products and endogenous mediators of inflammation could have resulted in increased adhesiveness of the cerebral vascular endothelium by induction of ELAM-1 like molecules with subsequent leucothrombus formation leading to cerebral infarction. It is noteworthy that anticardiolipin antibodies were absent in this patient.

We have thus reported a patient with SLE with major central nervous system disease resulting in death. The pathological findings suggest that the mechanism of infarction was related to leucothrombus formation. Further studies are needed to elucidate the pathogenetic mechanism involved.


Hammad, Tsukada, Torre
Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement.
A Hammad, Y Tsukada and N Torre

doi: 10.1136/ard.51.4.550

Updated information and services can be found at:
[http://ard.bmj.com/content/51/4/550](http://ard.bmj.com/content/51/4/550)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)